EXOZ
eXoZymes, Inc.
Biotechnology
Market Cap$84M
5Y Perf.-20.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
EXOZ vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
TMO
Thermo Fisher Scientific Inc.
Medical - Diagnostics & Research
Market Cap$176.36B
5Y Perf.-10.4%
EXOZ vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | EXOZ | TMO |
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $84M | $176.36B |
| Revenue (TTM) | $0.00 | $45.20B |
| Net Income (TTM) | $-8M | $6.86B |
| Gross Margin | — | 39.4% |
| Operating Margin | — | 17.8% |
| Forward P/E | — | 19.1x |
| Total Debt | $1M | $40.85B |
| Cash & Equiv. | $10M | $9.86B |
EXOZ vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
EXOZ
TMO
| Stock | Nov 24 | May 26 | Return |
|---|---|---|---|
| eXoZymes, Inc. (EXOZ) | 100 | 79.4 | -20.6% |
| Thermo Fisher Scien… (TMO) | 100 | 89.6 | -10.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EXOZ vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TMO leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. eXoZymes, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
EXOZ
eXoZymes, Inc.
The Income Pick
EXOZ is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.04
- Lower volatility, beta 1.04, Low D/E 13.3%, current ratio 8.12x
- Beta 1.04, current ratio 8.12x
Best for: income & stability and sleep-well-at-night
TMO
Thermo Fisher Scientific Inc.
The Growth Play
TMO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 3.9%, EPS growth 7.3%, 3Y rev CAGR -0.3%
- 229.1% 10Y total return vs EXOZ's 15.6%
- 3.9% revenue growth vs EXOZ's -65.6%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TMO | 3.9% revenue growth vs EXOZ's -65.6% |
| Quality / Margins | TMO | 15.2% margin vs EXOZ's 0.6% |
| Stability / Safety | EXOZ | Beta 1.04 vs TMO's 1.10, lower leverage |
| Dividends | TMO | 0.4% yield; 8-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | TMO | +16.8% vs EXOZ's -9.1% |
| Efficiency (ROA) | TMO | 6.4% ROA vs EXOZ's -108.0%, ROIC 7.5% vs -273.9% |
EXOZ vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
EXOZ vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTMOLAGGINGEXOZ
EXOZeXoZymes, Inc.
1leads
TMOThermo Fisher Scienti…
2leads
6 Total Categories
CATEGORYLEADERvs EXOZMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TMO1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TMO5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
EXOZ4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TMO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TMO and EXOZ operate at a comparable scale, with $45.2B and $0 in trailing revenue.
| Metric | EXOZeXoZymes, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $45.2B |
| EBITDAEarnings before interest/tax | -$9M | $10.5B |
| Net IncomeAfter-tax profit | -$8M | $6.9B |
| Free Cash FlowCash after capex | -$11M | $6.7B |
| Gross MarginGross profit ÷ Revenue | — | +39.4% |
| Operating MarginEBIT ÷ Revenue | — | +17.8% |
| Net MarginNet income ÷ Revenue | — | +15.2% |
| FCF MarginFCF ÷ Revenue | — | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -35.0% | +11.3% |
TMO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — EXOZ and TMO each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | EXOZeXoZymes, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| Market CapShares × price | $84M | $176.4B |
| Enterprise ValueMkt cap + debt − cash | $76M | $207.4B |
| Trailing P/EPrice ÷ TTM EPS | -13.89x | 26.75x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 19.11x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.67x |
| EV / EBITDAEnterprise value multiple | — | 19.04x |
| Price / SalesMarket cap ÷ Revenue | — | 3.96x |
| Price / BookPrice ÷ Book value/share | 7.80x | 3.34x |
| Price / FCFMarket cap ÷ FCF | — | 28.02x |
Evenly matched — EXOZ and TMO each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
TMO leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-155 for EXOZ. EXOZ carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x. On the Piotroski fundamental quality scale (0–9), TMO scores 6/9 vs EXOZ's 3/9, reflecting solid financial health.
| Metric | EXOZeXoZymes, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| ROE (TTM)Return on equity | -155.2% | +13.2% |
| ROA (TTM)Return on assets | -108.0% | +6.4% |
| ROICReturn on invested capital | -2.7% | +7.5% |
| ROCEReturn on capital employed | -92.4% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | 0.13x | 0.76x |
| Net DebtTotal debt minus cash | -$8M | $31.0B |
| Cash & Equiv.Liquid assets | $10M | $9.9B |
| Total DebtShort + long-term debt | $1M | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | — | 5.89x |
TMO leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
EXOZ leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in EXOZ five years ago would be worth $11,561 today (with dividends reinvested), compared to $10,283 for TMO. Over the past 12 months, TMO leads with a +16.8% total return vs EXOZ's -9.1%. The 3-year compound annual growth rate (CAGR) favors EXOZ at 5.0% vs TMO's -4.0% — a key indicator of consistent wealth creation.
| Metric | EXOZeXoZymes, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| YTD ReturnYear-to-date | -9.0% | -19.8% |
| 1-Year ReturnPast 12 months | -9.1% | +16.8% |
| 3-Year ReturnCumulative with dividends | +15.6% | -11.7% |
| 5-Year ReturnCumulative with dividends | +15.6% | +2.8% |
| 10-Year ReturnCumulative with dividends | +15.6% | +229.1% |
| CAGR (3Y)Annualised 3-year return | +5.0% | -4.0% |
EXOZ leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — EXOZ and TMO each lead in 1 of 2 comparable metrics.
Risk & Volatility
EXOZ is the less volatile stock with a 1.04 beta — it tends to amplify market swings less than TMO's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TMO currently trades 73.7% from its 52-week high vs EXOZ's 54.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EXOZeXoZymes, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.04x | 1.10x |
| 52-Week HighHighest price in past year | $18.40 | $643.99 |
| 52-Week LowLowest price in past year | $7.08 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +54.3% | +73.7% |
| RSI (14)Momentum oscillator 0–100 | 48.3 | 43.1 |
| Avg Volume (50D)Average daily shares traded | 5K | 1.9M |
Evenly matched — EXOZ and TMO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
TMO is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | EXOZeXoZymes, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $654.67 |
| # AnalystsCovering analysts | — | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 8 |
| Dividend / ShareAnnual DPS | — | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% |
Insufficient data to determine a leader in this category.
Key Takeaway
TMO leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). EXOZ leads in 1 (Total Returns). 2 tied.
Best OverallThermo Fisher Scientific In… (TMO)Leads 2 of 6 categories
Loading custom metrics...
EXOZ vs TMO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is EXOZ or TMO a better buy right now?
Thermo Fisher Scientific Inc.
(TMO) offers the better valuation at 26. 8x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EXOZ or TMO?
Over the past 5 years, eXoZymes, Inc.
(EXOZ) delivered a total return of +15. 6%, compared to +2. 8% for Thermo Fisher Scientific Inc. (TMO). Over 10 years, the gap is even starker: TMO returned +229. 1% versus EXOZ's +15. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EXOZ or TMO?
By beta (market sensitivity over 5 years), eXoZymes, Inc.
(EXOZ) is the lower-risk stock at 1. 04β versus Thermo Fisher Scientific Inc. 's 1. 10β — meaning TMO is approximately 6% more volatile than EXOZ relative to the S&P 500. On balance sheet safety, eXoZymes, Inc. (EXOZ) carries a lower debt/equity ratio of 13% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — EXOZ or TMO?
On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc.
grew EPS 7. 3% year-over-year, compared to -188. 0% for eXoZymes, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — EXOZ or TMO?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus 0. 0% for eXoZymes, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus 0. 0% for EXOZ. At the gross margin level — before operating expenses — TMO leads at 37. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — EXOZ or TMO?
In this comparison, TMO (0.
4% yield) pays a dividend. EXOZ does not pay a meaningful dividend and should not be held primarily for income.
07Is EXOZ or TMO better for a retirement portfolio?
For long-horizon retirement investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), +229. 1% 10Y return). Both have compounded well over 10 years (TMO: +229. 1%, EXOZ: +15. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between EXOZ and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.